

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/193817 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01) C07K 16/32 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2023/087277

(22) International Filing Date:

10 April 2023 (10.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/085838
08 April 2022 (08.04.2022) CN

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: ADAGENE PTE. LTD. [SG/SG]; 16 Raffles Quay, #33-03 Hong Leong Building, 048581 (SG).

(72) Inventor; and

(71) Applicant (for SC only): LUO, Peter Peizhi [US/CN]; 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: DU, Fangyong; 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). LI, Yan; 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). LIU, Guizhong; 4F, Building C14, 218 Xinghu St., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: WU, FENG & ZHANG; 3FL, Building 4, Yard 38, LinFengErLu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-CD28 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to anti-CD28 antibodies that bind to human CD28 and antigen-binding fragments thereof, compositions comprising same, and uses thereof in delaying and/or preventing tumor growth.

WO 2023/193817 A1